Drug Trial Radar · NCT06938529
A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function
Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Apr 18, 2025
Primary completion
Jul 15, 2025
Study completion Jul 25, 2025
Sponsor
- Lead sponsor
- Vincentage Pharma Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, non-randomized study to assess how VCT220 is absorbed, distributed, metabolized, and eliminated after a single oral dose. The study includes three groups: subjects with mild hepatic impairment (Child-Pugh Class A), subjects with moderate hepatic impairment (Child-Pugh Class B), and healthy subjects matched by gender, age, and body mass index (BMI). It will also explore the relationship between baseline liver function measures and the pharmacokinetic (PK) parameters of VCT220, to support appropriate dosing recommendations for patients with liver impairment.
Conditions
- Obesity, Overweight
Interventions
VCT220Drug
Small molecule GLP-1RA tablet, film coated
PlaceboDrug
VCT220 Placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak Plasma Concentration (Cmax) of VCT220Time frame: Predose up to 72 hours postdose (D1 to D4)
- Area Under the Serum Concentration Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of VCT220Time frame: Predose up to 72 hours postdose (D1 to D4)
- Area Under the Serum Concentration Curve From Time 0 to Infinity(AUC0-inf) of VCT220Time frame: Predose up to 72 hours postdose (D1 to D4)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Suzhou University
Suzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.